Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ondansetron

FDA-approved product (tablet, orally disintegrating, oral), marketed as Ondansetron, Zofran Odt, Zuplenz and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ondansetron
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Radiation-induced nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Serotonin (5ht3) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ondansetron in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ondansetron with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

    NCT01121042 · start 2010-07

    Registered record
    Registry ID
    NCT01121042
    Conditions
    Schizoaffective and Schizophreniform Disorders; Schizophrenia
    Interventions
    Ondansetron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2018-08
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizoaffective and Schizophreniform Disorders; Schizophrenia
    InterventionOndansetron; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children

    NCT01096797 · start 2009-11

    Registered record
    Registry ID
    NCT01096797
    Conditions
    Adenotonsillectomy; Postoperative Pain; Emergence Delirium
    Interventions
    Sevoflurane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenotonsillectomy; Postoperative Pain; Emergence Delirium
    InterventionSevoflurane
    PhasePhase 4
    Registry statusCompleted

  • Role of Anti-Inflammatory Agents in Patients With Schizophrenia

    NCT00929955 · start 2009-06

    Registered record
    Registry ID
    NCT00929955
    Conditions
    Schizophrenia; Schizoaffective Disorder; Psychosis Not Otherwise Specified; Schizophreniform Disorder
    Interventions
    Ondansetron; Simvastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2010-09
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Psychosis Not Otherwise Specified; Schizophreniform Disorder
    InterventionOndansetron; Simvastatin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.

    NCT01679093 · start 2009-06

    Registered record
    Registry ID
    NCT01679093
    Conditions
    Interaction Between Antiemetic Drugs and Paracetamol
    Interventions
    ondansetron; Droperidol; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-06
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInteraction Between Antiemetic Drugs and Paracetamol
    Interventionondansetron; Droperidol; Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

    NCT00878228 · start 2009-04

    Registered record
    Registry ID
    NCT00878228
    Conditions
    Nausea and Vomiting, Postoperative
    Interventions
    Ondansetron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-02
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Postoperative
    InterventionOndansetron; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

    NCT00819039 · start 2009-01-26

    Registered record
    Registry ID
    NCT00819039
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Aprepitant; Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01-26
    Completion
    2013-03-12
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAprepitant; Ondansetron
    PhasePhase 1
    Registry statusCompleted

  • Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

    NCT00738621 · start 2008-07

    Registered record
    Registry ID
    NCT00738621
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Aprepitant, Dexamethasone, Ondansetron; Aprepitant, Dexamethasone, Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAprepitant, Dexamethasone, Ondansetron; Aprepitant, Dexamethasone, Placebo
    PhasePhase 4
    Registry statusCompleted

  • Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy

    NCT01543945 · start 2008-03

    Registered record
    Registry ID
    NCT01543945
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Dexamethasone; Ondansetron; Dimenhydrinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    Not recorded
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionDexamethasone; Ondansetron; Dimenhydrinate
    PhasePhase 2
    Registry statusCompleted

  • Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

    NCT00429702 · start 2007-10

    Registered record
    Registry ID
    NCT00429702
    Conditions
    Nausea; Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    Decadron®; Benadryl®; Ativan®; ondansetron hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2009-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
    InterventionDecadron®; Benadryl®; Ativan®; ondansetron hydrochloride
    PhasePhase 2
    Registry statusTerminated

  • Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

    NCT00678457 · start 2007-01

    Registered record
    Registry ID
    NCT00678457
    Conditions
    Alcohol Dependence
    Interventions
    Ondansetron; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionOndansetron; Olanzapine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?

    NCT00547989 · start 2006-10

    Registered record
    Registry ID
    NCT00547989
    Conditions
    Breast Cancer
    Interventions
    standard anaesthesia (bupivacaine); additional pvb (ropivacaine) and elastomeric disposable infusion pump; additional pvb (ropivacaine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-10
    Completion
    2011-05
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionstandard anaesthesia (bupivacaine); additional pvb (ropivacaine) and elastomeric disposable infusion pump; additional pvb (ropivacaine)
    PhasePhase 3
    Registry statusCompleted

  • Cyclophosphamide Drug Interaction Study In Cancer Patients

    NCT00334646 · start 2005-08-10

    Registered record
    Registry ID
    NCT00334646
    Conditions
    Nausea and Vomiting, Chemotherapy-Induced
    Interventions
    Oral GW679769; IV Cyclophosphamide 500-700mg/m2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2005-08-10
    Completion
    2009-10-14
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Chemotherapy-Induced
    InterventionOral GW679769; IV Cyclophosphamide 500-700mg/m2
    PhasePhase 1
    Registry statusTerminated

  • Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

    NCT00649363 · start 2005-07

    Registered record
    Registry ID
    NCT00649363
    Conditions
    Healthy
    Interventions
    Ondansetron Orally Disintegrating Tablets 8 mg; Zofran ODT® Tablets 8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2005-07
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOndansetron Orally Disintegrating Tablets 8 mg; Zofran ODT® Tablets 8 mg
    PhasePhase 1
    Registry statusCompleted

  • Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

    NCT00104403 · start 2004-12

    Registered record
    Registry ID
    NCT00104403
    Conditions
    Nausea and Vomiting, Chemotherapy-Induced; Chemotherapy-Induced Nausea and Vomiting
    Interventions
    GW679769; Dexamethasone; Ondansetron Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-12
    Completion
    2006-01
    Enrolment
    722

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Chemotherapy-Induced; Chemotherapy-Induced Nausea and Vomiting
    InterventionGW679769; Dexamethasone; Ondansetron Hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

    NCT00090246 · start 2004-05-13

    Registered record
    Registry ID
    NCT00090246
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    MK0869, aprepitant; Comparator: ondansetron IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-05-13
    Completion
    2005-04-20
    Enrolment
    922

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionMK0869, aprepitant; Comparator: ondansetron IV
    PhasePhase 3
    Registry statusCompleted